🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Uveal Melanoma

Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis NCT07203391Phase 12 sites📍 Sydney📍 Melbourne St Vincent's Hospital, Sydney · Tests: roginolisib Tebentafusp-tebn With LDT in Metastatic UM NCT06626516Phase 1, Phase 21 site📍 Philadelphia Thomas Jefferson University · Tests: Tebentafusp-Tebn, GM-CSF (Sargramostim), BCNU Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma NCT07136181Phase 1, Phase 23 sites📍 Scottsdale📍 Denver📍 Nashville Novelwise Pharmaceutical Corporation · Tests: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of… Neoadjuvant Tebentafusp in Patients With Metastatic Uveal Melanoma NCT07057596Phase 24 sites📍 Berlin📍 L'Hospitalet de Llobregat📍 Madrid Grupo Español Multidisciplinar de Melanoma · Tests: Tebentafusp Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma NCT07276386Phase 21 site📍 Tampa H. Lee Moffitt Cancer Center and Research Institute · Tests: Melphalan/HDS (Percutaneous Hepatic Perfusion), Tebentafusp Neoadjuvant Tebentafusp for Uveal Melanoma NCT06414590Phase 22 sites📍 Philadelphia📍 Philadelphia Thomas Jefferson University · Tests: Tebentafusp-Tebn Adjuvant Melatonin for Uveal Melanoma NCT05502900Phase 31 site📍 Stockholm Gustav Stalhammar · Tests: Melatonin Neoadjuvant Darovasertib in Primary Uveal Melanoma NCT07015190Phase 394 sites📍 Scottsdale📍 La Jolla📍 Los Angeles IDEAYA Biosciences · Tests: Darovasertib, Primary Local Therapy Retrospective Register for Uveal Melanoma NCT05733728n/a1 site📍 Vienna Medical University of Vienna · Tests: any therapy suitable Follow-up of Patients With Uveal Melanoma Adapted to the Risk of Relapse (SALOME) NCT04424719NA1 site📍 Paris Institut Curie · Tests: Blood test Adjuvant Tebentafusp in High Risk Ocular Melanoma NCT06246149Phase 315 sites📍 Lake Success📍 Brussels📍 Nice European Organisation for Research and Treatment of Cancer … · Tests: Tebentafusp Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma NCT06550674NA1 site📍 Clermont-Ferrand Centre Jean Perrin · Tests: Constitutional exome analysis Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma NCT01438658n/a1 site📍 Jerusalem Hadassah Medical Organization Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors NCT04119024Phase 13 sites📍 Duarte📍 Los Angeles📍 Stanford Anusha Kalbasi · Tests: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma NCT07627698Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit NCT06805825Phase 15 sites📍 Ann Arbor📍 Cleveland📍 Portland Novelty Nobility, Inc. · Tests: NN3201 PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver Metastases NCT06519266Phase 36 sites📍 Gothenburg📍 Linköping📍 Lund Vastra Gotaland Region · Tests: PHP, IPI1/NIVO3, IPI3/NIVO1 Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours NCT04855435Phase 15 sites📍 Herlev📍 Barcelona📍 Madrid MonTa Biosciences ApS · Tests: MBS8(1V270), MBS8(1V270) and pembrolizumab combination ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors NCT03686124Phase 1, Phase 221 sites📍 Stanford📍 Aurora📍 Miami Immatics US, Inc. · Tests: IMA203 Product, IMA203 product- flat dose, IMA203CD8 Product, Nivolumab, IMADetect® Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver NCT07364474NA1 site📍 Boston Massachusetts General Hospital · Tests: Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with … Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome NCT04792463n/a1 site📍 Columbus Mohamed Abdel-Rahman A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel NCT06940739Phase 1, Phase 25 sites📍 Denver📍 Chapel Hill📍 Nashville Iovance Biotherapeutics, Inc. · Tests: IOV-3001 Adjuvant Quisinostat in High-Risk Uveal Melanoma NCT06932757Phase 21 site📍 Miami University of Miami · Tests: Quisinostat Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma NCT06627244Phase 21 site📍 Miami University of Miami · Tests: Tebentafusp, TheraSphere™ Yttrium-90 Trans-Arterial Radioembolization A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma NCT05607095Phase 12 sites📍 Harrison📍 New York Memorial Sloan Kettering Cancer Center · Tests: Lifileucel (LN-144/LN-145) Adding IL-2 to Tebentafusp to Eradicate Cancer Progression NCT07063875Phase 1, Phase 22 sites📍 Sydney📍 Melbourne St Vincent's Hospital, Sydney · Tests: Aldesleukin Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions NCT03947385Phase 1, Phase 215 sites📍 Los Angeles📍 San Francisco📍 Denver IDEAYA Biosciences · Tests: IDE196, Binimetinib, Crizotinib Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma NCT06070012Phase 24 sites📍 Aurora📍 Washington D.C.📍 Columbus Diwakar Davar · Tests: Tebentafusp A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors NCT07636785Phase 1, Phase 21 site📍 Scottsdale VM Discovery, Inc. · Tests: VMD-102
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy